« Return to News | Clinical Intelligence

EMA objects to Alexza’s Adasuve MAA

Tuesday, February 14, 2012 07:18 AM

Alexza Pharmaceuticals has received preliminary feedback, the Day 80 Assessment Report, from the European Medicines Agency (EMA) regarding its Marketing Authorization Application (MAA) for Adasuve, which seeks approval for the rapid control of agitation in adult patients with schizophrenia or bipolar disorder.

The EMA’s assessment report of Adasuve (Staccato loxapine) outlines major objections pertaining to the extrapolation of the phase III study population to the intended patient population, and pulmonary safety in patients with active airways disease. The EMA gave recommendations to address these issues via the risk management plan, other aspects of the risk management plan and the need to obtain an EU GMP certificate for the Alexza manufacturing facility and commercial manufacturing process. 

The next official EMA communication Alexza expects to receive will be the Day 120 notification and report, when the Committee for Medicinal Products for Human Use (CHMP) finalizes the list of review questions, the overall conclusions of scientific data and a listing of outstanding issues.

Alexza completed a Pre-Approval Inspection of its GMP commercial manufacturing facility by the FDA in December 2011 and believes it is well prepared for the EMA inspection of its facility.

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2012 CenterWatch.